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Background-—Third-generation P2Y12 antagonists (prasugrel and ticagrelor) are recommended in guidelines on ST-segment
elevation myocardial infarction. Mechanisms translating their more potent antiplatelet activity into improved clinical outcomes
versus the second-generation P2Y12 antagonist clopidogrel are unclear. The aim of this post hoc analysis of the Complete
Versus Lesion-Only PRImary PCI Trial-CMR (CvLPRIT-CMR) substudy was to assess whether prasugrel and ticagrelor were
associated with reduced infarct size compared with clopidogrel in patients undergoing primary percutaneous coronary
intervention.
Methods and Results-—CvLPRIT-CMR was a multicenter, prospective, randomized, open-label, blinded end point trial in 203 ST-
segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention
with either infarct-related artery–only or complete revascularization. P2Y12 inhibitors were administered according to local
guidelines. The primary end point of infarct size on cardiovascular magnetic resonance was not signiﬁcantly different between the
randomized groups. P2Y12 antagonist administration was not randomized. Patients receiving clopidogrel (n=70) compared with
those treated with either prasugrel or ticagrelor (n=133) were older (67.812 versus 61.510 years, P<0.001), more frequently
had hypertension (49% versus 29%, P=0.007), and tended to have longer symptom-to-revascularization time (234 versus
177 minutes, P=0.05). Infarct size (median 16.1% [quartiles 1–3, 10.5–27.7%] versus 12.1% [quartiles 1–3, 4.8–20.7%] of left
ventricular mass, P=0.013) and microvascular obstruction incidence (65.7% versus 48.9%, P=0.022) were signiﬁcantly greater in
patients receiving clopidogrel. Infarct size remained signiﬁcantly different after adjustment for important covariates using both
generalized linear models (P=0.048) and propensity score matching (P=0.025).
Conclusions-—In this analysis of CvLPRIT-CMR, third-generation P2Y12 antagonists were associated with smaller infarct size and
lower microvascular obstruction incidence versus the second-generation P2Y12 antagonist clopidogrel for ST-segment elevation
myocardial infarction.
Clinical Trial Registration-—URL: http://www.isrctn.com/ISRCTN70913605. ( J Am Heart Assoc. 2016;5:e003403 doi: 10.
1161/JAHA.116.003403)
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D ual antiplatelet therapy is a key component of manage-ment of ST-segment elevation myocardial infarction
(STEMI). Administration of a P2Y12 adenosine diphosphate
receptor antagonist in addition to aspirin is advocated by the
major international guidelines on STEMI management.1,2
Third-generation P2Y12 antagonists prasugrel and ticagrelor
are recommended based on improved clinical outcomes and
more potent platelet inhibition compared with the second-
generation prodrug clopidogrel. The large TRITON TIMI-38
(n=13 608)3 and PLATO (n=18 624)4 studies demonstrated
reduced medium-term combined major adverse cardiac
events (MACE) with prasugrel and ticagrelor, respectively,
compared with clopidogrel in acute coronary syndromes
including STEMI.3–5
Mechanisms translating the more potent antiplatelet
activity of prasugrel and ticagrelor into improved clinical
outcomes are unclear. Cardiovascular magnetic resonance
(CMR) accurately characterizes myocardial injury and function
following STEMI. Late gadolinium enhancement (LGE) imag-
ing–derived infarct size6 is a powerful medium-term prognos-
tic marker following primary percutaneous coronary
intervention (PPCI). A retrospective analysis of the INFUSE-
AMI trial demonstrated a trend toward reduced 30-day CMR
infarct size and reduced 12-month mortality with prasugrel
compared with clopidogrel in anterior STEMI treated with
PPCI.7 No other CMR data compare the effect of the third-
generation P2Y12 antagonists and clopidogrel after PPCI.
The primary aim of this post hoc analysis of Complete
Versus Lesion-Only PRImary PCI Trial-CMR (CvLPRIT-CMR)
substudy was to assess whether the third-generation P2Y12
antagonists prasugrel and ticagrelor were associated with
reduced infarct size compared with the second-generation
P2Y12 antagonist clopidogrel.
Methods
Study Design
The study design and main results were published previ-
ously.8,9 CvLPRIT-CMR was a prespeciﬁed substudy of a
multicenter, prospective, randomized, controlled, open-label,
clinical trial8 with blinded CMR end point analysis conducted at
7 UK centers between May 2011 and May 2014. Infarct size in
patients treated with complete revascularization and in those
treated with an infarct-related artery–only strategy was not
signiﬁcantly different.10 Inclusion and exclusion criteria were
the same as for the main trial with absolute contraindications
to CMR imaging as an additional exclusion. The study was
approved by the Trent Research Ethics Committee (reference
11/H0405/4) and conducted according to the Declaration of
Helsinki. Patients provided written informed consent.
Patient Recruitment and Treatment
STEMI patients presenting within 12 hours of symptom onset
were administered contemporary oral antiplatelet agents
according to local guidelines. All patients received aspirin
300 mg plus 1 P2Y12 antagonist: (1) clopidogrel (Plavix;
Sanoﬁ), 600-mg loading dose followed by 75-mg mainte-
nance; (2) prasugrel (Efﬁent; Daiichi-Sankyo), 60-mg loading
dose and 10 mg daily; or (3) ticagrelor (Brilique; AstraZeneca),
180-mg loading dose and then 90 mg twice daily. Adminis-
tration of the loading dose was permitted by paramedic staff
before hospital arrival or in hospital on arrival at the cardiac
catheterization room.
Angiographic Analysis
Pre- and post-PPCI epicardial coronary ﬂow was assessed using
Thrombolysis In Myocardial Infarction (TIMI) scoring.11 Collateral
ﬂow to the infarct-related artery (IRA) before PPCI was graded
using the Rentrop system.12 Quantitative coronary angiography
was undertaken using QAngioXA v1.0 software (Medis).
CMR Imaging
CMR was performed before discharge, and the methods were
described in detail previously.10 Brieﬂy, after localizers and long-
axis cine imaging, contiguous short-axis stacks covering the
entire left ventricle were acquired with (1) T2-weighted short s
inversion recovery to determine the ischemic area at risk
(edema), (2) steady-state free-precession cine imaging for left
ventricle volumetric analysis, and (3) LGE imaging to determine
infarct size and microvascular obstruction (MVO) after adminis-
tration of gadolinium contrast (0.2 mmol/kg Magnevist; Bayer).
CMR Analysis
CMR analysis was performed, as described previously, at the
University of Leicester core laboratory, blinded to all clinical
data including treatment allocation. If infarction was seen in
>1 coronary territory on acute CMR, this was recorded as
being in the IRA territory (associated edema and/or MVO) or
the non-IRA territory, with the consensus of 3 observers
(J.N.K., G.P.M., J.P.G.). Non-IRA infarcts were also classiﬁed as
likely to be acute or chronic (presence of wall thinning and no
edema or MVO). Infarct size was recorded for both IRA and
non-IRA LGE, and total infarct size was the sum of all LGE.
Clinical Outcomes and Follow-up
MACE was a composite of all-cause mortality, recurrent MI,
heart failure, and ischemia-driven revascularization. Second-
ary end points included individual components of the primary
end point. Safety end points comprised stroke, major
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bleeding, vascular access site injury, and contrast-induced
nephropathy. Data were collected by an independent clinical
trials unit (Royal Brompton Hospital), and events were
adjudicated by blinded clinicians.
Statistical Analysis
The primary CMR outcome was infarct size (expressed as
percentage of left ventricular mass) on CMR, analyzed on a
log-transformed scale due to right skew. This was adjusted for
known baseline predictors of infarct size (anterior myocardial
infarction, diabetes mellitus, TIMI ﬂow before PPCI, time to
revascularization) and important baseline variables that
signiﬁcantly differed between the 2 groups (age, hypertension
prevalence, timing of P2Y12 antagonist loading), using gener-
alized linear models. Propensity score–based stratiﬁcation
(quartiles) was also performed to adjust for the imbalance of
baseline covariates between the 2 groups.13 Starting with the
noted baseline covariates, the propensity score model was
built based on a backward selection process and the
assessment of balance between the 2 groups. Normally
distributed variables were expressed as meanSD and
compared using Student t tests. Nonnormally distributed
data were expressed as median (quartiles 1–3) and analyzed
using Mann–Whitney testing. Categorical variables were
compared using chi-square testing. Clinical outcomes were
assessed using time-to–ﬁrst event survival analysis (log-rank
test with right censoring), and Cox proportional hazards
models were ﬁtted to estimate hazard ratios and 95% CIs for
treatment comparisons.
Results
Baseline Characteristics
Patients receiving clopidogrel were slightly older
(67.812.3 years versus 61.59.6 years, P<0.001) and
had a higher prevalence of hypertension compared with
those receiving prasugrel or ticagrelor. Other baseline char-
acteristics and comorbidities were closely matched in
patients receiving clopidogrel and the third-generation P2Y12
antagonist agents and were similar to those in the overall
CvLPRIT study cohort (Table 1).
Baseline characteristics for patients receiving the 3 individ-
ual P2Y12 antagonists are shown in Table S1. Patients receiving
clopidogrel were older than those receiving prasugrel because
age >75 years is a contraindication to prasugrel therapy.
Angiographic and PCI Details
Details of angiography and PCI are shown in Table 2. There
was a trend toward longer median time from symptom onset
to revascularization in patients receiving clopidogrel (P=0.05).
Prehospital P2Y12 antagonist administration was more
Table 1. Baseline Characteristics of the Main CvLPRIT Study Population and Patients Receiving Clopidogrel and the Third-
Generation P2Y12 Antagonist Antiplatelet Agents (Prasugrel, Ticagrelor)
Variable
Main CvLPRIT
(n=296)
Newer P2Y12 Antagonists
(n=133) Clopidogrel (n=70) P Value
Age, y 64.911.6 61.59.6 67.812.3 <0.001
Male sex 240/296 (81.1) 114/133 (85.7) 56/70 (80.0) 0.29
Body mass index, kg/m2 27.3 (24.4–30.2) 27.5 (24.8–29.9) 27.6 (24.3–30.5) 0.61
Systolic blood pressure, mm Hg 137.627.1 133.5 (116–156) 137 (120–153) 0.86
Anterior infarct 106 (35.6) 46/133 (34.6) 26/70 (37.1) 0.72
Estimated glomerular filtration rate, mL/min/1.73 95.7434.7 100.029.0 87.737.3 0.013
Hypertension 105/287 (36.6) 39/133 (29.3) 34/70 (48.6) 0.007
Hypercholesterolemia 75/287 (26.1) 36/133 (27.1) 20/70 (28.6) 0.82
Diabetes mellitus 39/287 (13.6) 19/133 (14.3) 9/70 (12.9) 0.78
Current smoker 87/285 (30.5) 46/133 (34.6) 18/70 (25.7) 0.20
Previous myocardial infarction 12/287 (4.2) 4/133 (3.0) 4/70 (5.7) 0.35
Previous percutaneous coronary intervention 9/287 (3.1) 4/133 (3.0) 3/70 (4.3) 0.64
Antianginal medication, beta blockers or nitrates 54/287 (18.8) 18/132 (13.6) 15/70 (21.4) 0.16
Killip class II to III 24/286 (8.4) 11/133 (8.3) 5/70 (7.1) 0.78
Data expressed as meanSD, median (quartiles 1–3), or frequency (percentage) of patients, as appropriate. P values compare the treatment groups (clopidogrel vs third-generation P2Y12
antiplatelet agents).
CvLPRIT indicates Complete Versus Lesion-Only PRImary PCI Trial.
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Table 2. Periprocedural Details in Patients Receiving Clopidogrel and the Third-Generation P2Y12 Antiplatelet Agents (Prasugrel,
Ticagrelor)
Variable
Newer P2Y12 Antagonists
(n=133) Clopidogrel (n=70) P Value
Radial access 106/132 (80.3) 57/70 (81.4) 0.85
Time from symptoms to PCI (time to revascularization), min 177 (125–240) 234 (144–320) 0.051
Glycoprotein IIb/IIIa inhibitors 45/131 (34.4) 25/70 (35.7) 0.85
Bivalirudin 59/122 (48.4) 36/64 (56.2) 0.31
Visible thrombus 79/133 (59.8) 52/70 (74.3) 0.041
Thrombectomy catheter 89/132 (67.4) 57/70 (81.4) 0.034
Contrast dose, mL 220 (180–300) 250 (180–367.5) 0.13
Screening time, min 12 (8–19) 13 (8.25–18.75) 0.37
Procedure length, min 46 (31–70) 56.5 (40–74.3) 0.041
Quantitative coronary angiography, vessels with ≥75% stenosis 1.480.6 1.530.6 0.60
Quantitative coronary angiography, lesions ≥75% stenosis 1.590.7 1.660.7 0.51
Quantitative coronary angiography, stenosis in non–infarct-related artery lesions 72.012.3 70.810.6 0.49
SYNTAX score (total) 17.5 (13–22.5) 18 (14–23.5) 0.99
Left anterior descending infarct-related artery 48/133 (36.1) 24/70 (34.3) 0.80
Left circumflex infarct-related artery 26/133 (19.5) 12/70 (17.1) 0.68
Right coronary infarct-related artery 59/133 (44.4) 33/70 (47.1) 0.71
Rentrop grade 0 (0–1) 0 (0–1) 0.51
Rentrop grade 2–3 before PCI 6/133 (4.5) 7/70 (10.0) 0.13
Thrombolysis In Myocardial Infarction grade before PCI 0 (0–1), 0.581.0 0 (0–0), 0.360.8 0.95
Thrombolysis In Myocardial Infarction grade after PCI 3 (3–3), 2.770.5 3 (3–3), 2.920.4 0.39
Infarct-related artery, no reflow 6/133 (4.5) 4/70 (5.7) 0.71
Total number of stents 2 (1–3)
2.21.3
2 (1–3)
2.11.3
0.54
Drug-eluting stent use 127/133 (95.5) 66/70 (94.3) 0.71
Multivessel PCI (complete revascularization) 64/133 (48.1) 34/70 (48.6) 0.95
Peak CK, IU/L 992 (550–1631) 1214 (649–1960) 0.35
Aspirin 132/133 (99.2) 70/70 (100) 0.47
Timing of aspirin administration
Prehospital 113/124 (91.1) 56/67 (83.6) 0.12
In-hospital before angiogram 11/124 (8.9) 11/67 (16.4)
P2Y12 antagonist administration
Prehospital 11/132 (8.3) 17/64 (26.6) 0.001
In-hospital before angiogram 121/132 (91.7) 47/64 (73.4)
Discharge medication
Beta blocker 125/133 (94.0) 65/70 (92.9) 0.76
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 126/133 (94.7) 70/70 (100) 0.06
Lipid-lowering therapy 132/133 (99.3) 70/70 (100) 0.47
Loop diuretic 14/133 (10.5) 8/70 (11.3) 0.86
Aldosterone inhibitor 7/133 (5.3) 3/70 (4.3) 0.76
Data expressed as meanSD, median (quartiles 1–3), or frequency (percentage) of patients, as appropriate. P values compare the treatment groups (clopidogrel vs third-generation P2Y12
antiplatelet agents). CK indicates creatine kinase; PCI, percutaneous coronary intervention; SYNTAX, SYnergy between PCI with TAXus and cardiac surgery.
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common in patients receiving clopidogrel compared with
those receiving prasugrel or ticagrelor (P=0.001). There was a
higher prevalence of visible thrombus (P=0.041) and
thrombectomy catheter use (P=0.034) in patients receiving
clopidogrel. Complexity of coronary artery disease, prevalence
of well-collateralized IRA territory, use of glycoprotein IIb/IIIa
inhibitors and bivalirudin, and performance of multivessel PCI
were similar in patients receiving clopidogrel and prasugrel or
ticagrelor.
Approximately a quarter of patients receiving clopidogrel
and ticagrelor were administered loading doses before
arriving at the hospital; however, only 7% of prasugrel patients
were loaded before arrival (Table S1).
CMR Outcomes
CMR results are displayed in Table 3. CMR was undertaken at
a median of 2.9 days after PPCI in both groups. Left
ventricular volumes were similar in the 2 groups, and ejection
fraction was not signiﬁcantly different. Overall, 94% of
patients in each group demonstrated infarct on LGE. There
was a similar prevalence of multiple infarcts in patients
receiving clopidogrel and prasugrel or ticagrelor. The primary
end point of median total infarct size was signiﬁcantly larger
in patients receiving clopidogrel (16.1% [quartiles 1–3, 10.5–
27.7%] versus 12.1% [quartiles 1–3, 4.8–20.7%]) of left
ventricular mass, P=0.013). After adjustment for key covari-
ates, infarct size remained larger in patients receiving
Table 3. Acute Cardiovascular Magnetic Resonance Data in Patients Receiving Clopidogrel and the Third-Generation P2Y12
Antiplatelet Agents (Prasugrel, Ticagrelor)
Variable
Newer P2Y12
(Antagonists ((n=133)
Clopidogrel
(n=70) P Value
Acute cardiovascular magnetic resonance
Total infarct size, % LVM 12.1 (4.8–20.7) 16.1 (10.5–27.7) 0.013
0.048*
0.025†
Time to acute cardiovascular magnetic resonance, day 2.9 (1.9–4.1) 2.9 (2.0–3.8) 0.33
Infarct present on late gadolinium enhancement 124/133 (93.6) 66/70 (94.3) 0.77
Patients with >1 infarct 22/133 (16.5) 11/70 (15.7) 0.88
Patients with >1 acute infarct 14/133 (10.5) 8/70 (11.4) 0.84
Infarct-related artery infarct size (main infarct), % LVM 10.0 (4.4–18.9) 15.6 (9.8–26.3) 0.002
0.033*
0.011†
Non–infarct-related artery infarct size (total), % LVM 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.47
0.86*
Total infarct size (% LVM) of acute infarcts 10.6 (4.4–19.0) 16.0 (10.4–27.6) 0.013
0.034*
0.013†
Area at risk, % LVM‡ 32.812.9 36.811.4 0.07
Myocardial salvage index, % 63.3 (42.9–82.6) 46.2 (24.7–70.2) 0.06
0.12*
Microvascular obstruction present 65/133 (48.9) 46/70 (65.7) 0.022
Microvascular obstruction, % LVM* 0.0 (0–1.1) 0.25 (0–2.3) 0.06
0.49*
Left ventricular mass index, g/m2 51.7 (45.6–60.6) 52.6 (45.9–60.0) 0.99
Left ventricular end-diastolic volume index, mL/m2 89.5 (80.6–102.0) 91.1 (80.5–101.2) 0.62
Left ventricular end-systolic volume index, mL/m2 46.4 (37.9–60.6) 48.9 (41.6–59.3) 0.64
Left ventricular ejection fraction, % 46.010.5 44.47.8 0.20
Data expressed as meanSD, median (quartiles 1–3), or frequency (percentage) of patients, as appropriate. LVM indicates left ventricular mass.
*P value adjusted for known baseline predictors of infarct size (anterior myocardial infarction, time to revascularization, diabetes, Thrombolysis In Myocardial Infarction ﬂow before primary
percutaneous coronary intervention) and important baseline variables signiﬁcantly differing between the groups (age, hypertension prevalence, timing of P2Y12 antagonist loading) using
regression analysis.
†P value based on propensity score analysis with the propensity scores estimating from age, presence of hypertension, time to revascularization, and timing of P2Y12 antagonist loading.
‡Analyzable edema imaging available in 75% of patients in both groups.
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clopidogrel, using both generalized linear models (P=0.048)
and propensity score analysis (P=0.025). When chronic
infarcts were excluded, median total acute infarct size
(P=0.034) and median extent of the main IRA-related infarct
(P=0.033) were signiﬁcantly greater in the clopidogrel group
(Figure).
The prevalence of microvascular obstruction was higher in
patients receiving clopidogrel (65.7% versus 48.9%, P=0.022).
In 52 patients (26%), area at risk could not be reliably
quantiﬁed because no artifact but no edema was discernable
(n=33), imaging was not performed because of arrhythmia or
suboptimal breath holding (n=14), or severe artifact was
present (n=5). There was a trend toward lower myocardial
salvage index in the clopidogrel group (P=0.12).
CMR outcomes on an individual P2Y12 antagonist basis are
shown in Table S2. Total infarct size, IRA-related infarct size,
and total acute infarct size were similar in patients receiving
prasugrel and ticagrelor but were signiﬁcantly smaller with
both of these agents compared with clopidogrel.
Clinical Outcomes
Discharge medication was similar between the groups
(Table 2). Median follow-up was 368 days (clopidogrel group
355 days, prasugrel/ticagrelor group 372 days; P=0.05)
(Table 4). Length of inpatient stay was longer (4.43.6
versus 3.32.0, P=0.017) in patients receiving clopidogrel.
There was a nonsigniﬁcant trend toward reduced overall 12-
month MACE (17.1% versus 10.5%, P=0.18) driven mainly by a
reduced incidence of heart failure (P=0.04). There was no
difference in the incidence of safety end points between the
groups.
On an individual P2Y12 antagonist basis, there was a trend
toward reduced 12-month MACE with both prasugrel and
ticagrelor compared with clopidogrel (Tables S3–S5).
Discussion
This post hoc analysis of the CvLPRIT-CMR substudy partic-
ipants is, to our knowledge, the ﬁrst imaging-based study
assessing myocardial and microvascular injury associated
with the second-generation P2Y12 antagonist clopidogrel and
the third-generation P2Y12 antagonists prasugrel and tica-
grelor in STEMI. P2Y12 antagonism with prasugrel and
ticagrelor was associated with reduced total and IRA-
associated infarct size and reduced microvascular obstruction
incidence on CMR LGE imaging after PPCI. This post hoc
analysis was nonrandomized; therefore, there were baseline
differences, with higher age, prevalence of hypertension, and
prehospital administration of P2Y12 antagonists, and a trend
toward increased symptom time to reperfusion in patients
receiving clopidogrel. Despite adjusting for these variables
and known baseline predictors of infarct size, the results may
still suffer from biases and thus should be considered as
hypothesis generating but warranting investigation in larger
randomized studies.
Infarct Size and MVO
The greater total and IRA-related infarct size and incidence of
MVO in patients receiving clopidogrel may be inﬂuenced by
baseline differences, in particular, the trend toward longer
time to revascularization, which is a determinant of CMR
infarct size14,15 and prognosis in STEMI.16 Importantly, the
differences in infarct size and MVO incidence persisted after
correction for baseline differences in patient characteristics
and their known predictors. It is unlikely that patients
receiving clopidogrel had larger infarcts because the propor-
tion having anterior STEMI and Killip class were similar in the
groups, and there was greater prehospital clopidogrel admin-
istration.17 Although the prevalence of visible thrombus was
higher in the clopidogrel group, TIMI ﬂow grade before PPCI
and technical success at PPCI were similar, and the former
Figure. Median acute IS in patients receiving clopidogrel and the newer (third-generation P2Y12
antagonist) antiplatelet agents prasugrel (P) and ticagrelor (T). IRA indicates infarct-related artery; IS, infarct
size; LV, left ventricular.
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was adjusted to correct for higher thrombus burden. In
addition, all patients receiving clopidogrel had the larger 600-
mg loading dose, which, in a previous retrospective study in
198 patients, was associated with reduced CMR-derived
infarct size and MVO and increased myocardial salvage after
PPCI.18 The higher infarct size and MVO incidence occurred
despite a weak trend toward greater degree of IRA collater-
alization, which can attenuate infarct size and MVO,19,20 in the
patients receiving clopidogrel.
Our results are consistent with the only imaging-based
study comparing second- and third-generation P2Y12 antag-
onists. Brener et al7 demonstrated a strong trend toward
reduced total infarct size measured on CMR at 30 days with
prasugrel compared with clopidogrel in acute anterior STEMI
treated with PPCI (16.4% versus 17.6% left ventricular mass,
P=0.06). Our results are also supported by the ﬁndings of
Nanhwan et al,21 who demonstrated that ticagrelor but not
clopidogrel reduced infarct size in rats measured histologi-
cally.
The lower myocardial and microvascular injury observed in
patients receiving prasugrel and ticagrelor in our study may be
affected by the faster (peak effect after loading dose at
2 hours for ticagrelor, 4 hours for prasugrel, and 6 hours
after clopidogrel)22–24 and more potent23,25 antiplatelet
activity of these drugs compared with the prodrug clopidogrel.
Indeed, clopidogrel typically achieves a maximum of only 50%
platelet inhibition in combination with aspirin in acute
coronary syndromes compared with 90% with prasugrel
and aspirin26 and 94% with ticagrelor and aspirin.27 This
remains the case even when the larger 600-mg clopidogrel
loading dose is administered.22,25 In addition, the prodrug
forms only 15% of the clopidogrel metabolite, with 85% de-
esterised into an inactive carboxylic acid.28 Prasugrel has also
been shown to be associated with lower drug resistance than
clopidogrel. Brandt et al demonstrated that 42% of clopido-
grel-treated patients were associated with <20% platelet
noninhibition at 4 hours after administration compared with
0% of prasugrel-treated patients.25 This may be related to the
fact that prasugrel and ticagrelor metabolism have been
shown not to be affected by cytochrome P450 polymor-
phisms.28,29 It is interesting to speculate that prasugrel30 and
ticagrelor,21,31 which have anti-inﬂammatory and antiapop-
totic activity, may protect against reperfusion injury, which is
known to contribute to CMR-derived infarct size, MVO, and
intramyocardial hemorrhage.32
Clinical Outcomes
This study was not powered to detect differences in clinical
outcomes; however, we saw reduced incidence of heart failure
(P=0.04), with a weak nonsigniﬁcant trend toward reduced
combined 12-month MACE (17.1% versus 10.5%, P=0.18) with
the newer agents versus clopidogrel. These ﬁndings are
consistent with previous studies demonstrating improved
medium-term clinical outcomes with ticagrelor4 and prasug-
rel3,7,33,34 in STEMI, in particular, the work of Brener et al7
Table 4. Clinical Outcomes in Patients Receiving Clopidogrel and the Third-Generation P2Y12 Antiplatelet Agents (Prasugrel,
Ticagrelor)
Variable
Newer P2Y12
Antagonists
(n=133)
Clopidogrel
(n=70)
Hazard Ratio
(95% CI) P Value
12-month follow-up
Major adverse cardiac events 14/133 (10.5) 12/70 (17.1) 0.59 (0.27–1.3) 0.18
All-cause mortality 1/133 (0.8) 1/70 (1.4) 0.52 (0.03–8.5) 0.64
Recurrent myocardial infarction 3/133 (2.3) 0/70 (0.0) — 0.21
Type 1 2/133 (1.6) 0/70 (0.0) — 0.43
Type 4b 1/133 (0.8) 0/70 (0.0) — 0.66
Heart failure 2/133 (1.5) 5/70 (7.1) 0.20 (0.04–1.0) 0.04
Revascularization 8/133 (6.0) 6/70 (8.6) 0.66 (0.23–1.9) 0.45
Safety end points
Contrast nephropathy 1/133 (0.8) 0/70 (0.0) — 0.47
Vascular access injury 0/133 (0.0) 0/70 (0.0) — 1.00
Cerebrovascular accident/transient
ischemic attack
1/133 (0.8) 1/70 (1.4) 0.52 (0.03–8.5) 0.64
Major bleed 2/133 (1.6) 2/70 (2.9) 0.52 (0.07–3.8) 0.51
Data expressed as frequency (percentage) of patients.
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demonstrating reduced infarct size, mortality, and heart
failure at 12-month follow-up with prasugrel compared with
clopidogrel. The reduction in heart failure incidence in our
study could caused by the lower infarct size.
Limitations
In this post hoc analysis, patients were not randomized to a
particular P2Y12 antagonist. The differences in baseline
characteristics, in particular, symptom time to reperfusion,
may inﬂuence the observed differences in infarct size and
MVO incidence between the patients; however, our ﬁndings
persisted after correction for baseline differences and impor-
tant covariates. The study was not powered to detect
differences in clinical outcomes. Patients who died early or
who were unstable after PPCI were unlikely to have partic-
ipated in the CMR study, which may have underestimated
hard end points. We combined patients receiving prasugrel
and ticagrelor into a single group in the main analysis of this
study because of the relatively small number of patients
receiving ticagrelor (31 of 203 [15%]) and because patients
receiving these P2Y12 antagonists agents were very similar at
baseline and had similar infarct sizes.
Conclusions
In this post hoc analysis of the CvLPRIT study, patients with
multivessel coronary disease undergoing PPCI and receiving
prasugrel or ticagrelor had smaller total infarct size and
reduced incidence of MVO on CMR imaging compared with
those receiving clopidogrel. These ﬁndings persisted after
correction for baseline differences in patient characteristics
and important covariates. These ﬁndings may help explain the
improved clinical outcomes with the use of third-generation
antiplatelet agents compared with clopidogrel.
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Table S1: Baseline characteristics by dual antiplatelet agent received 
(Clopidogrel, Prasugrel, Ticagrelor)  
Variable Clopidogrel 
(n=70) 
Prasugrel 
(n=102) 
Ticagrelor 
(n=31) 
p 
Baseline characteristics     
Age (y) 67.8±12.2 60.8±9.1 63.0±11.4 <0.001 
Male sex (n, %) 57/70 (81.4) 86/101 (84.7) 29/32 (87.9) 0.55 
Anterior infarct (%) 26/70 (36.6) 36/101 (35.6) 11/32 (34.3) 0.95 
Hypertension (%) 34/70 (48.6) 27/101 (26.5) 12/32 (38.7) 0.012 
SYNTAX score (total) 18 (14-23.5) 18 (13.3-23.5) 16 (10-20.3) 0.16 
Symptom-PCI time (TTR, min)  227.5 (144-318) 169 (125-238) 177 (117-259) 0.16 
TIMI grade pre PCI 0 (0-0) 
0.36±0.8 
0 (0-1) 
0.49±0.9 
0 (0-2) 
0.87±1.3 
0.07 
TIMI grade post PCI  3 (3-3) 
2.9±0.4 
3 (3-3) 
2.9±0.4 
3 (3-3) 
2.9±0.3 
0.93 
Timing of DAPT administration  
• Pre-hospital (n, %) 
• In-hospital pre-angiogram (n, %) 
 
n=64 
17 (26.6) 
47 (73.4) 
n=102 
2 (7.1) 
99 (98.0) 
n=31 
9 (29.0) 
22 (71.0) 
 
<0.001 
 
PCI= percutaneous coronary intervention, TTR= time to revascularisation (symptom 
time), TIMI= thrombolysis in myocardial infarction; DAPT= dual antiplatelet 
therapy, SYNTAX= Synergy Between PCI With Taxus and Cardiac Surgery
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Table S2: Acute CMR data by dual antiplatelet agent received (Clopidogrel, 
Prasugrel, Ticagrelor)  
Variable Clopidogrel 
(n=70) 
Prasugrel 
(n=102) 
Ticagrelor 
(n=31) 
       p 
Acute CMR     
Total Infarct Size (% LVM) 
CvP p=0.040 
CvT p=0.002 
PvT p=0.26 
16.1 (10.5-27.7) 
 
 
12.2 (4.8-21.5) 
 
9.8 (3.5-16.5) 
 
0.002 
(0.026)* 
 
 
Time to acute CMR (d) 2.8 (2.0-3.7) 2.9 (1.9-4.1) 2.9 (1.9-4.1) 0.84 
Infarct present on LGE (n, %) 66/70 (94.3) 94/102 (92.2) 30/31 (96.8) 0.63 
Patients with >1 infarct 11/70 (15.7) 19/102 (18.6) 3/31 (9.7) 0.49 
Patients with >1 acute infarct 8/70 (11.4) 13/102 (12.7) 1/31 (3.4) 0.32 
IRA IS (main infarct, % LVM) 
CvP p=0.020 
CvT p=0.001 
PvT p=0.28 
15.6 (9.8-26.3) 
 
10.8 (4.8-19.2) 
 
8.9 (2.7-16.5) 
 
0.001 
(0.015)* 
NIRA IS (total, % LVM) 0.0 (0-0) 
 
0.0 (0-0) 
 
0.0 (0-0) 
 
0.55 
(0.88)* 
Total IS (% LVM) of acute 
infarcts 
CvP p=0.021 
CvT p=0.001 
PvT p=0.26 
16.0 (10.4-27.6) 
 
11.3 (4.8-19.9) 
 
9.8 (2.7-16.5) 
 
0.036 
(0.016)* 
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AAR (% LVM) 36.8±11.4 32.6±13.2 33.4±12.1 0.17 
Acute MSI (%) 
CvP p=0.12 
CvT p=0.003 
PvT p=0.19 
46.2 (24.7-70.2) 62.8 (31.9-81.3) 64.9 (56.9-93.0) 0.002 
(0.004)* 
MVO present (n %) 46/70 (65.7) 49/102 (44.1) 16/31 (51.6) 0.07 
MVO (% LVM) 0.25 (0-2.3) 0 (0-1.3) 0.05 (0-0.9) 0.17 
(0.63)* 
LVEDVI (ml/m2) 91.1 (80.5-101.2) 93.2 (83.3-104) 83.3 (76.3-98.4) 0.05 
LVESVI (ml/m2) 48.9 (41.6-59.3) 48.0 (39.0-62.1) 45.2 (35.3-53.3) 0.23 
LVEF (%) 44.2±7.8 46.0±10.9 46.1±9.4 0.53 
Wall motion score  23 (21-26) 22 (19-27) 22 (19.3-26) 0.60 
 
* p-value corrected for covariates  
 
IRA= Infarct related artery; LVMI= left ventricular mass index; LVEDVI= left 
ventricular end-diastolic volume index; LVESVI= left ventricular end-systolic 
volume index; LVEF= left ventricular ejection fraction; LGE= late gadolinium 
enhancement; NIRA= non-infarct related artery; IS=infarct size; AAR= area at risk; 
MVO= microvascular obstruction; MSI= myocardial salvage index 
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Table S3: Clinical outcomes in patients receiving Clopidogrel and Prasugrel 
 
Variable Clopidogrel 
(n=70) 
Prasugrel 
(n=102) 
HR (95% CI) 
 
p 
12 month follow-up     
MACE (n, %) 12/70 (17.1) 10/102 (9.8) 0.53 (0.21, 1.3) 0.17 
All-cause mortality (n, %) 1/70 (1.4) 1/102 (1.0) 0.68 (0.04, 11.1) 0.79 
Recurrent MI (n, %) 
• Type I 
• Type 4b (ST) 
0/70 (0.0) 
0/70 (0.0) 
0/70 (0.0) 
3/102 (2.9) 
2/102 (2.0) 
1/102 (1.0) 
** 
** 
** 
0.15 
0.24 
0.41 
Heart failure (n, %) 5/70 (7.1) 2/102 (2.0) 0.26 (0.05, 1.4) 0.11 
Revascularisation (n, %) 6/70 (8.6) 4/102 (3.9) 0.44 (0.12, 1.6) 0.20 
Safety Endpoints     
Contrast nephropathy (n, %) 0/70 (0.0) 1/102 (1.0) ** 0.41 
Vascular access injury (n, %) 0/70 (0.0) 0/102  (0.0) ** 1.00 
CVA/TIA (n, %) 0/70 (0.0) 0/102 (0.0) ** 1.00 
Major bleed (n, %) 1/70 (1.4) 1/102 (1.0) 0.68 (0.04, 11.1) 0.79 
 
MACE= major adverse cardiovascular event, ST= stent thrombosis, CV= 
cardiovascular, CVA= cerebrovascular accident
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Table S4: Clinical outcomes in patients receiving Clopidogrel and Ticagrelor 
 
Variable Clopidogrel 
(n=70) 
Ticagrelor 
(n=31) 
HR (95% CI) 
 
p 
12 month follow-up     
MACE (n, %) 12/70 (17.1) 4/31 (12.9) 0.72 (0.21, 2.4) 0.54 
All-cause mortality (n, %) 
• CV mortality 
• Non-CV mortality 
1/70 (1.4) 
1/70 (1.4) 
0/70 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
** 
** 
** 
0.50 
0.50 
1.00 
Recurrent MI (n, %) 
• Type I 
• Type 4b (ST) 
0/70 (0.0) 
0/70 (0.0) 
0/70 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
** 
** 
** 
1.00 
1.00 
1.00 
Heart failure (n, %) 5/70 (7.1) 0/31 (0.0) ** 0.12 
Revascularisation (n, %) 6/70 (8.6) 4/31 (12.9) 1.58 (0.41, 6.1) 0.56 
Safety Endpoints     
Contrast nephropathy (n, %) 0/70 (0.0) 0/31 (0.0) ** 1.00 
Vascular access injury (n, %) 0/70 (0.0) 0/31  (0.0) ** 1.00 
CVA/TIA (n, %) 0/70 (0.0) 0/31 (0.0) ** 1.00 
Major bleed (n, %) 1/70 (1.4) 0/31 (0.0) ** 0.50 
 
MACE= major adverse cardiovascular event, ST= stent thrombosis, CV= 
cardiovascular, CVA= cerebrovascular accident
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Table S5: Clinical outcomes in patients receiving Prasugrel and Ticagrelor 
 
Variable Prasugrel 
(n=102) 
Ticagrelor 
(n=31) 
HR (95% CI) 
 
p 
12 month follow-up     
MACE (n, %) 10/102 (9.8) 4/31 (12.9) 1.36 (0.40, 4.7) 0.65 
All-cause mortality (n, %) 
• CV mortality 
• Non-CV mortality 
1/102 (1.0) 
1/70 (1.4) 
0/70 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
** 
** 
** 
0.58 
0.58 
1.00 
Recurrent MI (n, %) 
• Type I 
• Type 4b (ST) 
3/102 (2.9) 
2/102 (2.0) 
1/102 (1.0) 
0/31 (0.0) 
0/31 (0.0) 
0/31 (0.0) 
** 
** 
** 
0.34 
0.43 
0.58 
Heart failure (n, %) 2/102 (2.0) 0/31 (0.0) ** 
0.43 
Revascularisation (n, %) 4/102 (3.9) 4/31 (12.9) 3.63 (0.85, 15.5) 0.07 
Safety Endpoints     
Contrast nephropathy (n, %) 1/102 (1.0) 0/31 (0.0) ** 0.58 
Vascular access injury (n, %) 0/102 (0.0) 0/31  (0.0) ** 1.00 
CVA/TIA (n, %) 0/102 (0.0) 0/31 (0.0) ** 1.00 
Major bleed (n, %) 1/102 (1.0) 0/31 (0.0) ** 0.58 
 
MACE= major adverse cardiovascular event, ST= stent thrombosis, CV= 
cardiovascular, CVA= cerebrovascular accident  
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